These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24677271)

  • 21. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.
    Goettsch C; Hutcheson JD; Hagita S; Rogers MA; Creager MD; Pham T; Choi J; Mlynarchik AK; Pieper B; Kjolby M; Aikawa M; Aikawa E
    Atherosclerosis; 2016 Aug; 251():109-118. PubMed ID: 27318830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerating the pace of atherosclerosis research.
    Daugherty A; Tabas I; Rader DJ
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):11-2. PubMed ID: 25520521
    [No Abstract]   [Full Text] [Related]  

  • 23. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low carbohydrate, high protein diet promotes atherosclerosis in apolipoprotein E/low-density lipoprotein receptor double knockout mice (apoE/LDLR(-/-)).
    Kostogrys RB; Franczyk-Żarów M; Maślak E; Gajda M; Mateuszuk L; Jackson CL; Chłopicki S
    Atherosclerosis; 2012 Aug; 223(2):327-31. PubMed ID: 22771189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice.
    Osman E; Evans V; Graham IR; Athanasopoulos T; McIntosh J; Nathwani AC; Simons JP; Dickson G; Owen JS
    Atherosclerosis; 2009 May; 204(1):121-6. PubMed ID: 18930458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
    Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
    Shen L; Peng HC; Nees SN; Zhao SP; Xu DY
    FEBS Lett; 2013 May; 587(9):1271-4. PubMed ID: 23499248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice.
    Xu M; Wu X; Liu Z; Ding Y; Kong W; Little PJ; Xu S; Weng J
    Biochem Biophys Res Commun; 2022 Sep; 622():163-169. PubMed ID: 35868060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis of PCSK9 function.
    Lambert G; Charlton F; Rye KA; Piper DE
    Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
    Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adeno-associated viruses as a method to induce atherosclerosis in mice and hamsters.
    Zelcer N; Westerterp M
    Circ Res; 2014 May; 114(11):1672-4. PubMed ID: 24855195
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.
    Beutner F; Brendel D; Teupser D; Sass K; Baber R; Mueller M; Ceglarek U; Thiery J
    Atherosclerosis; 2012 Jun; 222(2):337-43. PubMed ID: 22446027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
    Kumar S; Kang DW; Rezvan A; Jo H
    Lab Invest; 2017 Aug; 97(8):935-945. PubMed ID: 28504688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD; Kim JB; Wasserman SM; Lambert G
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice.
    Li MW; Mian MO; Barhoumi T; Rehman A; Mann K; Paradis P; Schiffrin EL
    Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2306-15. PubMed ID: 23887640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.